## Victoria C Yan

## List of Publications by Year in Descending Order

Source: https://exaly.com/author-pdf/7581957/victoria-c-yan-publications-by-year.pdf

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

21 198 6 13 g-index

30 328 7.9 4.36 ext. papers ext. citations avg, IF L-index

#	Paper	IF	Citations
21	Phosphoramidate Prodrugs Continue to Deliver: The Journey of Remdesivir (GS-5734) from the Liver to Peripheral Blood Mononuclear Cells <i>ACS Medicinal Chemistry Letters</i> , <b>2022</b> , 13, 520-523	4.3	
20	Remdesivir for COVID-19: Why Not Dose Higher?. Antimicrobial Agents and Chemotherapy, 2021, 65,	5.9	5
19	Homozygous MTAP deletion in primary human glioblastoma is not associated with elevation of methylthioadenosine. <i>Nature Communications</i> , <b>2021</b> , 12, 4228	17.4	3
18	Pharmacokinetics of Orally Administered GS-441524 in Dogs <b>2021</b> ,		5
17	Why Remdesivir Failed: Preclinical Assumptions Overestimate the Clinical Efficacy of Remdesivir for COVID-19 and Ebola. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2021</b> , 65, e0111721	5.9	7
16	Targeting Host Glycolysis as a Strategy for Antimalarial Development. <i>Frontiers in Cellular and Infection Microbiology</i> , <b>2021</b> , 11, 730413	5.9	2
15	Single-Cell RNA Sequencing Supports Preferential Bioactivation of Remdesivir in the Liver. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2021</b> , 65, e0133321	5.9	O
14	NEAT1 is essential for metabolic changes that promote breast cancer growth and metastasis. <i>Cell Metabolism</i> , <b>2021</b> , 33, 2380-2397.e9	24.6	10
13	An enolase inhibitor for the targeted treatment of ENO1-deleted cancers. <i>Nature Metabolism</i> , <b>2020</b> , 2, 1413-1426	14.6	14
12	Advantages of the Parent Nucleoside GS-441524 over Remdesivir for Covid-19 Treatment. <i>ACS Medicinal Chemistry Letters</i> , <b>2020</b> , 11, 1361-1366	4.3	86
11	Why Great Mitotic Inhibitors Make Poor Cancer Drugs. <i>Trends in Cancer</i> , <b>2020</b> , 6, 924-941	12.5	17
10	Bioreducible Phosphonoamidate Pro-drug Inhibitor of Enolase: Proof of Concept Study. <i>ACS Medicinal Chemistry Letters</i> , <b>2020</b> , 11, 1484-1489	4.3	2
9	Captisol and GS-704277, but Not GS-441524, Are Credible Mediators of Remdesivir Nephrotoxicity. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2020</b> , 64,	5.9	6
8	Aliphatic amines are viable pro-drug moieties in phosphonoamidate drugs. <i>Bioorganic and Medicinal Chemistry Letters</i> , <b>2020</b> , 30, 127656	2.9	1
7	Antimicrobial Prodrug Activation by the Staphylococcal Glyoxalase GloB. <i>ACS Infectious Diseases</i> , <b>2020</b> , 6, 3064-3075	5.5	4
6	The 3 Enantiomer Drives Enolase Inhibitory Activity in SF2312 and Its Analogues. <i>Molecules</i> , <b>2019</b> , 24,	4.8	6
5	Caspase-3 Substrates for Noninvasive Pharmacodynamic Imaging of Apoptosis by PET/CT. <i>Bioconjugate Chemistry</i> , <b>2018</b> , 29, 3180-3195	6.3	15

## LIST OF PUBLICATIONS

4	Expedient Method for Direct Mono-amidation of Phosphonic and Phosphoric Acids	2
3	Comprehensive Summary Supporting Clinical Investigation of GS-441524 for Covid-19 Treatment	6
2	Aliphatic Amines are Viable Pro-drug Moieties in Phosphonoamidate Drugs	1
1	Eradication of ENO1-deleted Glioblastoma through Collateral Lethality	3